Thiazolidinediones for nonalcoholic steatohepatitis - Promising but not ready for prime time

New England Journal of Medicine

Volumn 355, Issue 22, 2006, Pages 2361-2363

  McCullough, Arthur J ^a  

^a CASE WESTERN RESERVE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ALPHA ADRENERGIC RECEPTOR STIMULATING AGENT; ANTIBIOTIC AGENT; ANTIOXIDANT; BETAINE; CANNABINOID RECEPTOR ANTAGONIST; CASPASE INHIBITOR; CLOFIBRATE; GEMFIBROZIL; INCRETIN; INSULIN; METFORMIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PIOGLITAZONE; PLACEBO; PROBIOTIC AGENT; PROBUCOL; ROSIGLITAZONE; S ADENOSYLMETHIONINE; TETRAHYDROLIPSTATIN; URSODEOXYCHOLIC ACID;

CLINICAL TRIAL; EDITORIAL; HISTOPATHOLOGY; HUMAN; INSULIN RESISTANCE; INSULIN SENSITIVITY; MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONALCOHOLIC FATTY LIVER; PRIORITY JOURNAL; TREATMENT OUTCOME;

DIABETES MELLITUS, TYPE 2; FATTY LIVER; HEPATITIS; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN RESISTANCE; THIAZOLIDINEDIONES;

EID: 33751523274     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMe068232     Document Type: Editorial

References (15)

1. Browning JD, Szczepaniak LS, Dobbins R, et al. Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology 2004;40:1387-95.
2. Chitturi S, Farrell GC, George J. Non-alcoholic steatohepatitis in the Asia-Pacific region: future shock. J Gastroenterol Hepatol 2004;19:368-74.
3. McCullough AJ. The epidemiology and risk factors of NASH. In: Farrell GC, George J, Hall P, McCullough AJ eds. Fatty liver disease: NASH and related disorders. Malden, MA: Blackwell, 2005:23-37.
4. Matteoni CA, Younossi ZM, Gramlich T, Boparai N, Liu YC, McCullogh AJ. Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterology 1999;116:1413-9.
5. Hui JM, Kench JG, Chitturi S, et al. Long-term outcomes of cirrhosis in nonalcoholic steatohepatitis compared with hepatitis C. Hepatology 2003;38:420-7.
6. Ratziu V, Bonyhay L, DiMartino V, et al. Survival, liver failure, and hepatocellular carcinoma in obesity-related cryptogenic cirrhosis. Hepatology 2002;35:1485-93.
7. McCullough AJ. Pathophysiology of nonalcoholic steatohepatitis. J Clin Gastroenterol 2006;40:Suppl 1:S17-S29.
8. Marchesini G, Brizi M, Bianchi G, et al. Nonalcoholic fatty liver disease: a feature of the metabolic syndrome. Diabetes 2001;50:1844-50.
9. Sanyal AJ, Campbell-Sargent C, Mirshahi F, et al. Nonalcoholic steatohepatitis: association of insulin resistance and mitochondrial abnormalities. Gastroenterology 2001;120:1183-92.
10. Bugianesi E, Gentilcore F, Manini R, et al. A randomized controlled trial of metformin versus vitamin E or prescriptive diet in nonalcoholic fatty liver disease. Am J Gastroenterol 2005;100:1082-90.
11. Promrat K, Lutchman G, Uwaifo GI, et al. A pilot study of pioglitazone treatment for nonalcoholic steatohepatitis. Hepatology 2004;39:188-96.
12. Neuschwander-Tetri BA, Brunt EM, Wehmeier KR, Oliver D, Bacon BR. Improved nonalcoholic steatohepatitis after 48 weeks of treatment with PPAR-gamma ligand rosiglitazone. Hepatology 2003;38:1008-17.
13. Sanyal AJ, Mofrad PS, Contos MJ, et al. A pilot study of vitamin E versus vitamin E and pioglitazone for the treatment of nonalcoholic steatohepatitis. Clin Gastroenterol Hepatol 2004;2:1107-15.
14. Tiikkainen M, Hakkinen AM, Korsheninnikova E, Nyman T, Makimattila S, Yki-Jarvinen H. Effects of rosiglitazone and metformin on liver fat content, hepatic insulin resistance, insulin clearance, and gene expression in adipose tissue in patients with type 2 diabetes. Diabetes 2004;53:2169-76.
15. Belfort R, Harrison SA, Brown K, et al. A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. N Engl J Med 2006;355:2297-307.